Fenimore Asset Management Inc purchased a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 6,110 shares of the medical research company's stock, valued at approximately $3,063,000.

• The Market Is Selling Everything, but These 5 Stocks Aren't Breaking Down

Other hedge funds have also recently bought and sold shares of the company. Assetmark Inc. increased its holdings in Thermo Fisher Scientific by 22.9% in the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company's stock valued at $21,819,000 after buying an additional 7,023 shares during the last quarter. North Dakota State Investment Board bought a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $7,505,000. Boston Trust Walden Corp grew its position in shares of Thermo Fisher Scientific by 9.7% in the 4th quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company's stock worth $25,480,000 after acquiring an additional 3,873 shares in the last quarter. Xponance LLC increased its holdings in shares of Thermo Fisher Scientific by 8.1% in the 4th quarter. Xponance LLC now owns 59,295 shares of the medical research company's stock valued at $34,358,000 after acquiring an additional 4,436 shares during the last quarter. Finally, Merit Financial Group LLC raised its position in shares of Thermo Fisher Scientific by 34.0% during the 4th quarter. Merit Financial Group LLC now owns 15,504 shares of the medical research company's stock valued at $8,984,000 after acquiring an additional 3,934 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Michael D. Shafer sold 25,500 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares of the company's stock, valued at approximately $12,596,400. This represents a 54.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $565.00, for a total transaction of $226,000.00. Following the transaction, the chief operating officer owned 24,651 shares in the company, valued at $13,927,815. This represents a 1.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 52,053 shares of company stock worth $30,643,589 in the last three months. Insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

• The Often-Missed Corner of Healthcare That Wall Street Is Loving

TMO has been the subject of a number of research reports. Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 price objective for the company. Robert W. Baird decreased their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating for the company in a report on Friday, April 24th. Sanford C. Bernstein assumed coverage on shares of Thermo Fisher Scientific in a research report on Friday, June 26th. They set a "market perform" rating and a $520.00 price objective for the company. Jefferies Financial Group reissued a "buy" rating and issued a $630.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Finally, Weiss Ratings upgraded Thermo Fisher Scientific from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $619.41.

Read Our Latest Stock Analysis on Thermo Fisher Scientific

Thermo Fisher Scientific Stock Down 1.1%

• Sector Rotation: 2 Smart Money Moves for 2026

Shares of Thermo Fisher Scientific stock opened at $596.65 on Friday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $643.99. The business's fifty day moving average price is $527.07 and its two-hundred day moving average price is $509.02. The company has a market capitalization of $220.61 billion, a P/E ratio of 32.10, a PEG ratio of 2.45 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same period last year, the company earned $4.28 earnings per share. The company's quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.11%.

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Read More

• Five stocks we like better than Thermo Fisher Scientific
• Asian Market Circuit Breakers Hit Stocks, Not AI Demand
• Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
• Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
• Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Thermo Fisher Scientific Right Now?

Before you consider Thermo Fisher Scientific, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.

While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here